Egyptian Journal of Medical Human Genetics · 2016 · 16 citations · 30 references
Life SciencesBiochemistryPharmacotherapyEnzymologyGene TherapyNeurodegenerationEnzyme DeficienciesGenetic DisordersLysosomal BiochemistryLysosomal Storage DisordersNeurodegenerative DisordersSafety Of Gene TherapyEnzyme Replacement TherapyGaucher DiseaseGene-targeted TherapyGlucocerebrosidase TherapyLysosomal Storage DefectsOral TreatmentPharmacological ChaperoningSubstrate Reduction Therapy
Gaucher disease is the most common lysosomal storage disorder due to deficiency of ß-glucocerebrosidase. Since the introduction of Ceredase in 1991, enzyme replacement therapy has been the mainstay of treatment with its major disadvantage of long life dependency on biweekly IV therapy. It was more than a decade later when the substrate reduction therapy – an oral treatment – was approved for Gaucher disease. Future therapeutic modalities will include pharmacological chaperon and possibly gene therapy. The aim of this review is to high light the current and future treatment options for patients with Gaucher disease and to compare their effects and side effects.
30
Neal J. Weinreb, Joel Charrow, Hans C. Andersson et al. · The American Journal of Medicine · 2002 · 541 citations
Pramod K. Mistry, Jun Liu, Mei Yang et al. · Proceedings of the National Academy of Sciences · 2010 · 250 citations
Randomized, controlled trial of miglustat in Gaucher's disease type 3
Raphael Schiffmann, Edmond J. FitzGibbon, Chris Harris et al. · Annals of Neurology · 2008 · 233 citations · Full text
Medicine, Neurology, Pharmacotherapy +14